Thoracoscopic thymectomy for juvenile myasthenia gravis

Area of Science:

• Pediatric Surgery
• Neurology
• Immunology

Background:

• Myasthenia gravis (MG) is a rare autoimmune disorder affecting neuromuscular junctions.
• While thymectomy improves outcomes in adult MG, data on juvenile MG (JMG), particularly with minimally invasive techniques, are limited.
• This study addresses the gap in understanding thoracoscopic thymectomy for JMG.

Purpose of the Study:

• To review the experience with thoracoscopic thymectomy for juvenile myasthenia gravis (JMG).
• To evaluate the safety and efficacy of this minimally invasive approach in a pediatric cohort.
• To assess clinical outcomes and medication use post-surgery.

Main Methods:

• Retrospective review of 50 JMG patients undergoing thoracoscopic thymectomy (2007-2018).
• Utilized a left thoracoscopic approach with extended dissection, avoiding monopolar energy.
• Collected demographics, diagnostic criteria, clinical classification, surgical data, and follow-up clinical status/medications.

Main Results:

• The average age of surgical patients was 10.5 years.
• The cohort was evenly split between ocular and generalized JMG.
• No complications, morbidity, or mortality were observed; 49.8% showed improvement at follow-up (up to 3.5 years), with a trend towards reduced steroid use.

Conclusions:

• Thoracoscopic thymectomy is a safe and effective treatment for JMG across various patient profiles.
• Pediatric patients undergoing thymectomy demonstrate improved clinical status.
• This approach contributes to reduced medication requirements in JMG patients.